急诊普外科围术期血糖控制与术后并发症:血浆糖化血红蛋白的作用
该研究对前瞻性维护的急诊普外科数据库进行3年分析,纳入术前3个月内测过HbA1c的402例患者,按HbA1c<6与≥6分为两组。总体49%患者HbA1c≥6%,死亡率6%,主要并发症发生率7.9%。HbA1c≥6%组并发症率36% vs 11%(p<0.001),但两组死亡率无差异(p=0.09)。控制混杂后,HbA1c≥6.0%(OR 2.9,p<0.01)与术后随机血糖≥200 mg/dL(OR 2.3,p<0.01)是主要并发症的独立预测因素,两者并存时OR为4.2(p<0.01)。作者结论认为术前HbA1c可分层识别术后易发生高血糖的患者, regardless of preoperative RBS。
要点
- 急诊普外科患者中HbA1c≥6.0%者术后并发症率36%,显著高于HbA1c<6%者的11%(p<0.001)。
- 控制混杂后,HbA1c≥6.0%(OR 2.9,p<0.01)和术后随机血糖≥200 mg/dL(OR 2.3,p<0.01)均为主要并发症独立预测因素。
- HbA1c≥6.0%且术后随机血糖≥200 mg/dL者,主要并发症OR为4.2(p<0.01)。
- 两组死亡率无差异(p=0.09)。
- 校正混杂后,较高HbA1c与较高术后随机血糖独立相关(b=0.494,[19.7-28.4],p=0.02),但与术前随机血糖无相关性。
适用人群与场景
- 接受急诊普外科手术、且在术前3个月内测量过HbA1c的患者。
- 研究共纳入402例,平均年龄61±12岁,53%为女性,63.8%为糖尿病患者。
诊断标准与关键阈值
- 按术前HbA1c水平分为两组:HbA1c<6与HbA1c≥6。
- 术后随机血糖(RBS)阈值为200 mg/dL。
研究设计与关键结果
- 研究类型为对前瞻性维护的急诊普外科数据库进行3年分析,样本量402例,人群为急诊普外科手术患者。
- 总体49%患者HbA1c≥6%,死亡率6%,主要并发症发生率7.9%。
- HbA1c≥6%组并发症率36% vs HbA1c<6%组11%(p<0.001);两组死亡率无差异(p=0.09)。
- 控制混杂后,HbA1c≥6.0%(OR 2.9,p<0.01)和术后随机血糖≥200 mg/dL(OR 2.3,p<0.01)是主要并发症的独立预测因素。
- HbA1c≥6.0%且术后随机血糖≥200 mg/dL者主要并发症OR为4.2(p<0.01)。
- 校正混杂后,较高HbA1c与较高术后随机血糖独立相关(b=0.494,[19.7-28.4],p=0.02),但与术前随机血糖无相关性。
- 高血压、冠心病史、BMI≥30 kg/m²的患者更可能HbA1c≥6.0%。
证据类型、等级与局限
- 证据类型:预后研究,证据等级为level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,术前HbA1c可分层识别术后易发生高血糖的患者, regardless of preoperative RBS。
- 作者结论认为,HbA1c≥6.0%且术后随机血糖≥200 mg/dL的急诊普外科患者发生主要并发症的风险约为对照的4倍。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Plasma hemoglobin A1c (HbA1c) reflects quality of glucose control in diabetic patients. Literature reports that patients undergoing surgery with an elevated HbA1c level are associated with increased postoperative morbidity and mortality. The aim of our study was to evaluate the impact of HbA1c level on outcomes after emergency general surgery (EGS).
METHODS: We performed a 3-year analysis of our prospectively maintained EGS database. Patients who had HbA1c levels measured within 3 months before surgery were included. Patients were divided into two groups (HbA1c < 6 and HbA1c ≥ 6). Our primary outcome measures included in-hospital complications (major and minor complications), hospital and intensive care unit length of stay, and mortality. Secondary outcomes measures were 30-day complications, readmissions, and mortality. Multivariate and linear regressions were performed.
RESULTS: Of the 402 study patients, mean age was 61 ± 12 years, 53% were females, and 63.8% were diabetics. Overall, 49% had an HbA1c ≥ 6%; the mortality rate was 6%. Those with hypertension, history of coronary artery disease, and body mass index of 30 kg/m or greater were more likely to have HbA1c of 6.0% or greater. 7.9% patients experienced major complications. Patients with HbA1c of 6% or greater had a higher complication rate (36% vs 11%, p < 0.001) than those with HbA1c less than 6%. However there was no difference in mortality between two groups (p = 0.09). After controlling for confounders, HbA1c ≥ 6.0% (odds ratio [OR], 2.9; p < 0.01) and a postoperative random blood sugar (RBS) of 200 mg/dL or greater (OR, 2.3; p < 0.01) were independent predictors of major complications. Patients with both HbA1c of 6.0% or greater and postoperative RBS of 200 or greater had higher odds (OR, 4.2; p < 0.01) of developing major complication. After adjusting for confounders, a higher HbA1c was independently correlated with a higher postoperative RBS (b = 0.494, [19.7-28.4], p = 0.02), but there was no correlation with the preoperative RBS.
CONCLUSION: Patients with HbA1c of 6.0% or greater and a postoperative RBS of 200 mg/dL or greater have a four times higher risk of developing major complications after EGS. A preoperative HbA1c can stratify patients prone to develop postoperative hyperglycemia, regardless of their preoperative RBS.
LEVEL OF EVIDENCE: Prognostic, level III.
参考来源
- Jehan F, Khan M, Sakran JV, et al. Perioperative glycemic control and postoperative complications in patients undergoing emergency general surgery: What is the role of Plasma Hemoglobin A1c? J Trauma Acute Care Surg. 2018. PMID: 29040204. doi:10.1097/TA.0000000000001724
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。